JP2003535893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003535893A5 JP2003535893A5 JP2002503273A JP2002503273A JP2003535893A5 JP 2003535893 A5 JP2003535893 A5 JP 2003535893A5 JP 2002503273 A JP2002503273 A JP 2002503273A JP 2002503273 A JP2002503273 A JP 2002503273A JP 2003535893 A5 JP2003535893 A5 JP 2003535893A5
- Authority
- JP
- Japan
- Prior art keywords
- propofol
- pharmaceutical composition
- parenteral administration
- aqueous pharmaceutical
- administration according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 55
- 229960004134 propofol Drugs 0.000 description 55
- 238000007911 parenteral administration Methods 0.000 description 30
- 239000008194 pharmaceutical composition Substances 0.000 description 30
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 20
- 229920000858 Cyclodextrin Polymers 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000006201 parenteral dosage form Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000007981 phosphate-citrate buffer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000003708 ampul Substances 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN573MU2000 IN187686B (enExample) | 2000-06-21 | 2000-06-21 | |
| IN573/MUM/2000 | 2000-06-21 | ||
| PCT/IN2000/000124 WO2001097796A1 (en) | 2000-06-21 | 2000-12-14 | Clear aqueous anaesthetic composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003535893A JP2003535893A (ja) | 2003-12-02 |
| JP2003535893A5 true JP2003535893A5 (enExample) | 2008-02-07 |
| JP4907833B2 JP4907833B2 (ja) | 2012-04-04 |
Family
ID=11097257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002503273A Expired - Fee Related JP4907833B2 (ja) | 2000-06-21 | 2000-12-14 | 透明水性麻酔剤組成物 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7138387B2 (enExample) |
| EP (1) | EP1299095B1 (enExample) |
| JP (1) | JP4907833B2 (enExample) |
| KR (1) | KR100810066B1 (enExample) |
| CN (1) | CN1254237C (enExample) |
| AP (1) | AP2002002674A0 (enExample) |
| AT (1) | ATE267592T1 (enExample) |
| AU (2) | AU3597201A (enExample) |
| BG (1) | BG107463A (enExample) |
| BR (1) | BR0017268A (enExample) |
| CA (1) | CA2414064C (enExample) |
| DE (1) | DE60011149T2 (enExample) |
| DK (1) | DK1299095T3 (enExample) |
| EA (1) | EA005589B1 (enExample) |
| ES (1) | ES2222271T3 (enExample) |
| HU (1) | HUP0301646A3 (enExample) |
| IL (1) | IL153387A0 (enExample) |
| IN (1) | IN187686B (enExample) |
| MX (1) | MXPA02012611A (enExample) |
| NO (1) | NO20025999L (enExample) |
| NZ (1) | NZ523643A (enExample) |
| PL (1) | PL359624A1 (enExample) |
| PT (1) | PT1299095E (enExample) |
| WO (1) | WO2001097796A1 (enExample) |
| YU (1) | YU2703A (enExample) |
| ZA (1) | ZA200300336B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN188917B (enExample) * | 2000-12-07 | 2002-11-23 | Bharat Surums & Vaccines Ltd | |
| US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| CA2470500C (en) * | 2001-12-28 | 2012-05-15 | Guilford Pharmaceuticals, Inc. | Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol |
| JP2005522422A (ja) * | 2002-02-01 | 2005-07-28 | シモダ、バイオテック（プロプライエタリー）リミテッド | 医薬組成物 |
| BR0313060A (pt) * | 2002-07-29 | 2005-06-28 | Transform Pharmaceuticals Inc | Composições farmacêuticas aquosas de 2,6-diisopropilfenol |
| US7550155B2 (en) | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
| DK1585548T3 (en) * | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| US20090192230A1 (en) * | 2004-01-14 | 2009-07-30 | Koichi Takeda | Propofol-containing fat emulsion preparation |
| WO2006030450A2 (en) * | 2004-09-13 | 2006-03-23 | Bharat Serums & Vaccines Ltd. | Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy |
| CN101287447B (zh) * | 2005-08-12 | 2012-10-24 | 印度血清及疫苗有限公司 | 包含丙泊酚的水性麻醉剂组合物 |
| WO2007128866A2 (en) * | 2006-05-09 | 2007-11-15 | Novobion Oy | Novel chemical compositions |
| US8663874B2 (en) * | 2008-03-11 | 2014-03-04 | 3M Innovative Properties Company | Hardcoat composition |
| WO2010148288A2 (en) * | 2009-06-19 | 2010-12-23 | Lyotropic Therapeutics, Inc. | Pharmaceutical formulations with low aqueous levels of free unbound drug |
| CN102597116B (zh) | 2009-07-21 | 2013-12-11 | 3M创新有限公司 | 可固化组合物、涂覆底片的方法、以及被涂覆的底片 |
| WO2011034847A1 (en) | 2009-09-16 | 2011-03-24 | 3M Innovative Properties Company | Fluorinated coating and phototools made therewith |
| WO2011034845A1 (en) | 2009-09-16 | 2011-03-24 | 3M Innovative Properties Company | Fluorinated coating and phototools made therewith |
| US8268067B2 (en) * | 2009-10-06 | 2012-09-18 | 3M Innovative Properties Company | Perfluoropolyether coating composition for hard surfaces |
| EP2345427A1 (de) * | 2010-01-14 | 2011-07-20 | SapioTec GmbH | Flurankomplex |
| DK2484350T3 (en) * | 2011-02-04 | 2016-08-01 | Norbert Univ -Prof Dr Med Roewer | A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt |
| AU2013273764B2 (en) * | 2011-11-29 | 2016-05-05 | Zoetis Services Llc | Pharmaceutical compositions |
| KR101922752B1 (ko) * | 2011-11-29 | 2018-11-27 | 주록스 피티와이 리미티드 | 사이클로덱스트린 및 소수성 약물을 포함하는 주사용 약제학적 조성물을 보존하는 방법 |
| CN103263404B (zh) * | 2012-04-28 | 2017-12-01 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种复合麻醉药物 |
| PL2887944T3 (pl) | 2012-08-21 | 2022-02-21 | Sage Therapeutics, Inc. | Allopregnanolon do leczenia lekoopornego stanu padaczkowego |
| EP3407875A4 (en) * | 2016-01-29 | 2019-09-04 | Cuda Anesthetics, LLC | AQUEOUS PHARMACEUTICAL FORMULATION WITH PROPOFOL |
| FR3117337B1 (fr) | 2020-12-10 | 2023-04-28 | Centre Hospitalier Univ De Lille | Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA962214B (en) * | 1995-04-10 | 1996-10-07 | Farmarc Nederland Bv | Pharmaceutical composition |
-
2000
- 2000-06-21 IN IN573MU2000 patent/IN187686B/en unknown
- 2000-12-14 NZ NZ523643A patent/NZ523643A/en not_active IP Right Cessation
- 2000-12-14 AU AU3597201A patent/AU3597201A/xx active Pending
- 2000-12-14 EA EA200300047A patent/EA005589B1/ru not_active IP Right Cessation
- 2000-12-14 PT PT00991825T patent/PT1299095E/pt unknown
- 2000-12-14 BR BR0017268-5A patent/BR0017268A/pt not_active Application Discontinuation
- 2000-12-14 HU HU0301646A patent/HUP0301646A3/hu unknown
- 2000-12-14 DE DE60011149T patent/DE60011149T2/de not_active Expired - Lifetime
- 2000-12-14 DK DK00991825T patent/DK1299095T3/da active
- 2000-12-14 WO PCT/IN2000/000124 patent/WO2001097796A1/en not_active Ceased
- 2000-12-14 KR KR1020027017362A patent/KR100810066B1/ko not_active Expired - Fee Related
- 2000-12-14 US US10/296,765 patent/US7138387B2/en not_active Expired - Lifetime
- 2000-12-14 MX MXPA02012611A patent/MXPA02012611A/es active IP Right Grant
- 2000-12-14 CN CNB008198292A patent/CN1254237C/zh not_active Expired - Fee Related
- 2000-12-14 AT AT00991825T patent/ATE267592T1/de active
- 2000-12-14 PL PL00359624A patent/PL359624A1/xx unknown
- 2000-12-14 AP APAP/P/2002/002674A patent/AP2002002674A0/en unknown
- 2000-12-14 ES ES00991825T patent/ES2222271T3/es not_active Expired - Lifetime
- 2000-12-14 IL IL15338700A patent/IL153387A0/xx not_active IP Right Cessation
- 2000-12-14 AU AU2001235972A patent/AU2001235972B2/en not_active Ceased
- 2000-12-14 JP JP2002503273A patent/JP4907833B2/ja not_active Expired - Fee Related
- 2000-12-14 YU YU2703A patent/YU2703A/sh unknown
- 2000-12-14 CA CA2414064A patent/CA2414064C/en not_active Expired - Fee Related
- 2000-12-14 EP EP00991825A patent/EP1299095B1/en not_active Expired - Lifetime
-
2002
- 2002-12-13 NO NO20025999A patent/NO20025999L/no not_active Application Discontinuation
-
2003
- 2003-01-13 ZA ZA200300336A patent/ZA200300336B/en unknown
- 2003-01-16 BG BG107463A patent/BG107463A/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003535893A5 (enExample) | ||
| EP0193287B1 (en) | Etoposide preparations | |
| JP4907833B2 (ja) | 透明水性麻酔剤組成物 | |
| US7678776B2 (en) | Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof | |
| AU2001235972A1 (en) | Clear aqueous anaesthetic composition | |
| WO2002102383A1 (fr) | Preparation de cilostazol aqueuse pour injections | |
| RU2003119556A (ru) | Прозрачные стабильные композиции пропофола | |
| EP1680144B1 (en) | Methylphenidate solution and associated methods of administration and production | |
| CN1046516C (zh) | 化合物dx－52－1的稳定方法和其冻干组合物 | |
| JP3917820B2 (ja) | オザグレルナトリウム含有注射液およびその安定化方法 | |
| EP0953359A1 (en) | Pharmaceutical composition for oral administration | |
| CA2486571C (en) | Pharmaceutical composition | |
| JPS6216929B2 (enExample) | ||
| CN1034132A (zh) | 含哌啶基环戊基庚烯酸衍生物的水溶液配方 | |
| CN1559387A (zh) | 辅酶q10静脉输注注射液及其制备方法 | |
| JP2003137782A (ja) | 高濃度塩酸ニカルジピン含有製剤 | |
| WO2014108791A1 (en) | Injectable composition containing chlorothiazide | |
| JPS58121300A (ja) | フルオロメトロン包接化合物、その製造法およびそれを有効成分とする抗炎症剤 | |
| HK1081451B (en) | Medicinal composition |